All of these factors may have led to an underestimation of the proportion of participants continuing to provide VCT services.
The proportion of patients continuing on study drug and TA following a VTE ranged from 47 to 83%.
In addition, for the subset of patients with available in-hospital medication data, we described the proportion of patients continuing metformin use between hospital admission and ICU admission.
The proportion of patients continuing metformin use, even after a first decline brought the eGFR below 30 mL/min/1.73 m, was 44% in Denmark and 62% in the UK.
Three studies used the medication possession ratios [ 20, 27, 59], while others measured the proportion of patients continuing treatment [ 33, 38, 42, 43, 67, 68, 70].
The proportion of participants continuing to self-monitor over time was ascertained from the interview data, while the proportion of time in therapeutic range (TTR) was calculated using the INR data.
Successful self-monitoring was defined as the proportion of participants: continuing to self-monitor for 12 months; not experiencing adverse events over the 12 months; and achieving >80%TTR.
The proportion of patients continuing to experience any seizure related symptom (e.g., aura, nondisabling seizures) is greater, particularly after longer periods after surgery [de Tisi et al., 2011].
The proportion of patients continuing monitoring over 24 months remained high in both treatment cohorts; this may refect the increase in basal insulin dose and inclusion of a prandial component in the regimen of some patients in the insulin cohort over the course of the study.
If we apply the 12-month proportion of continuing DMPA use for CHW-initiated clients (63%), this would suggest an incremental cost per CYP of approximately US$16.
